Azitra, Inc. (AZTR)
- Previous Close
0.1880 - Open
0.1850 - Bid 0.1720 x 900
- Ask 0.1890 x 1400
- Day's Range
0.1710 - 0.1881 - 52 Week Range
0.1610 - 5.1800 - Volume
885,976 - Avg. Volume
793,813 - Market Cap (intraday)
5.415M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.8300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.50
Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.
azitrainc.comRecent News: AZTR
Performance Overview: AZTR
Trailing total returns as of 5/14/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AZTR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AZTR
Valuation Measures
Market Cap
5.42M
Enterprise Value
4.51M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.90
Price/Book (mrq)
1.86
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-77.51%
Return on Equity (ttm)
-6,496.54%
Revenue (ttm)
686k
Net Income Avi to Common (ttm)
-12.64M
Diluted EPS (ttm)
-1.8300
Balance Sheet and Cash Flow
Total Cash (mrq)
1.8M
Total Debt/Equity (mrq)
30.41%
Levered Free Cash Flow (ttm)
-5.14M
Research Analysis: AZTR
Company Insights: AZTR
AZTR does not have Company Insights